Basic Information
Emadine
Regulatory Information
EMEA/H/C/000223
Authorised
January 27, 1999
28
July 10, 2022
Company Information
Sweden
Solnavagen 3H 113 63 Stockholm
Immedica Pharma Ab
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of seasonal allergic conjunctivitis.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).